Development of Apratoxin S10 (Apra S10) as an Anti-pancreatic Cancer Agent and Its Preliminary Evaluation in an Orthotopic Patient-derived Xenograft (PDX) Model

Despite the significant progress in the field of cancer therapeutics, the incidence of pancreatic cancer (PC) has continuously increased. One possible mechanism for this increasing burden is impaired drug delivery and drug resistance resulting from a unique tumor microenvironment and genetic mutatio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Cai, Weijing, Ratnayake, Ranjala, Gerber, Michael H., Chen, Qi-Yin, Yu, Yichao, Derendorf, Hartmut, Trevino, Jose G., Luesch, Hendrik
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360136/
https://ncbi.nlm.nih.gov/pubmed/30073464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0647-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller